Drugs / OCT-980
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07408232 | Mar 2026 → Nov 2028 expected | retinitis pigmentosa | Octant, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | Octant, Inc. | Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa octant.bio ↗ |
| 2026-03-10 | Octant, Inc. | Octant Announces First Healthy Volunteer Dosed in Phase 1/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa octant.bio ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCT-980 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07408232 ↗ |
| Modality | Small molecule | “an oral small molecule corrector” NCT07408232 ↗ |
| Route | Oral | “OCT-980 capsules administered orally once at dose levels specified in the protocol” NCT07408232 ↗ |